Leukocyte and Platelet-Rich Fibrin (LPRF) Therapy & Leprosy: the Need for Caution and Research Among Marginalised Groups in Low Resource Settings

Abstract

This paper discusses the potential of Leukocyte and Platelet-Rich Fibrin Therapy (LPRF) to help treat ulcers and skin damage associated with leprosy. It warns that although LPRF may be a valuable and cost-effective treatment, it is crucial to understand potential resistance to haematologically based treatments. For physicians and health service staff operating within a biomedical paradigm, folk beliefs resisting such treatments may be inconsequential. However, research and education among marginalised and excluded populations is vital to overcome potential hesitancy and resistance to such treatments.